AXGN

Over the past six months, Axogen's stock price increased significantly, reaching $44.23 on September 18, 2026, a 157.15% rise from $17.20 on September 19, 2025, with a 52-week range of $15.27 to $52.91. Key events include strong Q2 2026 results, where revenue grew 23.1% to $69.7 million, exceeding estimates and leading to an 8.5% stock rally and raised full-year revenue guidance to at least $279 million. Analyst coverage from Truist Securities initiated a 'Buy' rating with a $60 price target, while H.C. Wainwright and Citizens raised their targets to $53 and $55, respectively, with a consensus target of $51.56 to $53.90. On September 10, 2026, Axogen announced the acquisition of BioCircuit Technologies and priced a $208.7 million public offering of common stock. However, the stock has also seen insider selling by directors and executives in August and May 2026, and has faced valuation concerns, profit-taking, broader market weakness, and rising interest rate concerns.